Table 4.

Incidence of adverse events (≥ 2%) with fluvoxamine in postmarketing studies (n = 34 587)

Adverse event	Incidence (%)
Nausea	15.7
Somnolence	6.4
Asthenia	5.1
Headache	4.8
Dry mouth	4.8
Insomnia	4.0
Dizziness	3.7
Abdominal pain	3.5
Vomiting	3.5
Dyspepsia	3.2
Constipation	3.2
Nervousness	3.2
Tremor	2.8
Diarrhea	2.4
Anorexia	2.2

Adapted from Wagner et al (1994).